

JC12 Rec'd PCT/PTC 19 OCT 2005

PATENT

Customer No. 22,852

Attorney Docket No. 07680.0023-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
LEDBETTER et al.)	Group Art Unit: Not Yet Assigned
)	
Application No.: Not Yet Assigned)	Examiner: Not Yet Assigned
)	
Filed: Herewith)	
)	
For: TGF-BETA ANTAGONISTS)	Confirmation No.: Not Yet Assigned
COMBINED WITH RENIN-)	
ANGIOTENSIN-ALDOSTERON-)	
SYSTEM ANTAGONISTS FOR)	
TREATING RENAL INSUFFICIENCY)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application and before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Customer No. 22,852
 Attorney Docket No. 07680.0023-00000

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
 GARRETT & DUNNER, L.L.P.

Dated: October 19, 2005

By: 
 Leslie A. McDonell
 Reg. No. 34,872

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known 10/553595	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Herewith (October 28, 2005)
				First Named Inventor	Steven Ledbetter et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	07680.0023-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁹
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 00/66631	9 Nov 2000	Cambridge Antibody Technology Limited		
		WO 01/66140 A1	13 Sept 2001	Genzyme Corporation		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁹
		Benigni et al., "Add-On Anti-TGF- β Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat," <i>J. Am. Soc. Nephrol.</i> , 14:1816-1824 (2003)	
		Chen et al., "Reversibility of Established Diabetic Glomerulopathy by Anti-TGF- β Antibodies in <i>db/db</i> Mice," <i>BBRC</i> , 300:16-22 (2003)	
		Gaedeke et al., "Angiotensin II and Progressive Renal Insufficiency," <i>Current Hypertension Reports</i> , 4:403-407 (2002)	
		Ling et al., "Therapeutic Role of TGF- β -Neutralizing Antibody in Mouse Cyclosporin A Nephropathy: Morphologic Improvement Associated with Functional Preservation," <i>J. Am. Soc. Nephrol.</i> , 14:377-388 (2003)	
		Zoja et al., "How to Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach," <i>J. Am. Soc. Nephrol.</i> , 13:2898-2908 (2002)	

Examiner Signature	/David Romeo/ (06/10/2008)	Date Considered	
-----------------------	----------------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.